No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Sandoz’s Denosumab Biosimilar Launched in Canada
On 16 July 2024, Sandoz announced the Canadian launch of Wyost® (denosumab), biosimilar to Amgen’s Xgeva®. Wyost® is available as a 120 mg subcutaneous injection for use every four weeks. Wyost® was the first denosumab biosimilar approved in Canada in March 2024 for...